Status and phase
Conditions
Treatments
Study type
Funder types
Identifiers
About
Primary purpose of the clinical study is to evaluate the safety, biodistribution and radiation dosimetry of [131I]-SGMIB Anti-HER2 VHH1 in healthy volunteers and patients with HER2+ breast cancer.
Secondary purpose of the clinical study is to evaluate the tumor uptake of [131I]-SGMIB Anti-HER2 VHH1 in patients with HER2+ breast cancer.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Subjects will only be included in the study if they meet all of the following criteria:
Patients will only be included in the study if they meet all of the following criteria:
Exclusion criteria
Patients will not be included in the study if one of the following criteria applies:
Subjects will not be included in the study if one of the following criteria applies:
Primary purpose
Allocation
Interventional model
Masking
9 participants in 1 patient group
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal